Private vs NHS Weight Loss Treatment

In the UK you can access weight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) either through the NHS or privately. NHS treatment costs no more than a standard prescription charge, includes multidisciplinary support and follows NICE criteria, but eligibility is narrow and waits can be long. Private treatment is available to a much wider group within the medicines' licences and is usually quicker to start, but you pay the full cost and the quality of support varies between providers. Whichever route you take, the decision to prescribe belongs to a registered prescriber. This guide compares the two in detail.

How weight management is organised on the NHS

NHS weight management in England is often described in tiers. The terminology varies between areas and is gradually changing, but the broad structure is:

Weight loss medicines have traditionally been prescribed mainly in tier 3 services, which have limited capacity and long waiting lists in many areas. The NHS roll-out of Mounjaro is extending access into primary care for some people, supported by new wraparound services to help with diet and physical activity.

NICE guideline NG246 sets out the overall approach to identifying and managing overweight and obesity, including lower BMI thresholds for people from some ethnic backgrounds. See our guide to BMI thresholds and ethnicity.

Which medicines are available on the NHS

Wegovy (semaglutide)

NICE TA875, published in March 2023, recommends semaglutide for managing overweight and obesity in adults within a specialist weight management service, for a maximum of two years. It is recommended for people with at least one weight-related condition and a BMI of at least 35, or 30 to 34.9 if they meet criteria for referral to specialist services, with lower thresholds for some ethnic groups. See Wegovy on the NHS.

Mounjaro (tirzepatide)

NICE TA1026, published in December 2024, recommends tirzepatide for adults with a BMI of at least 35 and at least one weight-related condition, with lower thresholds for some ethnic groups. Because of the large number of people eligible, NICE agreed a funding variation allowing NHS England to phase access over a longer period.

NHS England's interim commissioning guidance set out three initial cohorts for primary care:

The five qualifying conditions are type 2 diabetes, high blood pressure, heart disease (established atherosclerotic cardiovascular disease), obstructive sleep apnoea and abnormal blood fats (dyslipidaemia). Local implementation varies between integrated care boards, so ask your GP what is available in your area. See Mounjaro on the NHS.

Saxenda (liraglutide) and orlistat

NICE TA664 recommends liraglutide for a narrow group within specialist services: people with a BMI of 35 or more, non-diabetic hyperglycaemia and a high risk of cardiovascular disease. Orlistat, a tablet that reduces fat absorption, has long been available on NHS prescription and is sometimes used in primary care. See orlistat vs GLP-1s.

Newer tablets

At the time of writing, the MHRA has authorised the Wegovy tablet (oral semaglutide) and Foundayo (orforglipron) for weight management, but neither had completed NICE appraisal for routine NHS use. Check NICE and your GP for the latest position. See our oral GLP-1 guide.

Scotland, Wales and Northern Ireland

NICE guidance applies in England and is generally adopted in Wales and Northern Ireland. In Scotland, the Scottish Medicines Consortium (SMC) makes its own decisions, and NHS boards organise services locally. Access and timelines may therefore differ across the four nations. Your GP or local health board can tell you what applies to you.

How private treatment works

Private weight loss treatment is mostly provided by online pharmacies and online doctor services, as well as some high-street pharmacies and private clinics. A typical process looks like this:

1. Online consultation. You complete a detailed medical questionnaire covering your health, medicines and history.
2. Verification. The provider checks your identity and age, and verifies your weight and height, for example by video consultation, photo or video evidence, or confirmation from your GP. General Pharmaceutical Council (GPhC) guidance strengthened in 2025 expects this kind of independent verification for weight loss medicines.
3. Prescriber review. A registered prescriber reviews your information and decides whether a medicine is appropriate. They may ask further questions or decline to prescribe.
4. Dispensing and delivery. A GPhC-registered pharmacy dispenses the medicine and sends it in temperature-controlled packaging.
5. Ongoing reviews. Before each dose increase or repeat supply, the provider checks progress, side effects and any changes in your health.

Private prescribers work within the medicine's licence. For Mounjaro and Wegovy, that means adults with a BMI of 30 or more, or 27 to 30 with at least one weight-related condition, alongside a reduced-calorie diet and increased activity. A prescriber should decline if treatment is not safe or appropriate. Our guide to online weight loss consultations explains what to expect.

Side-by-side comparison

Advantages and drawbacks of each route

NHS treatment

Potential advantages:

• minimal cost to you
• care from a multidisciplinary team, often including dietitians and psychologists
• integrated with your GP record and other NHS care
• structured diet and physical activity support alongside medication
• access to other treatments, such as bariatric surgery referral, where appropriate

Potential drawbacks:

• narrow eligibility, especially in the early stages of the Mounjaro roll-out
• long waits for specialist services in many areas
• variation in what is available locally
• time limits for some medicines, such as two years for Wegovy under TA875

Private treatment

Potential advantages:

• available to more people, within the licence
• usually faster to start
• choice of provider and, in discussion with the prescriber, of medicine
• convenience of online consultations and home delivery

Potential drawbacks:

• you pay the full cost, which can rise with dose and with list-price changes, such as the September 2025 Mounjaro price rise
• the level of clinical support varies
• less integration with your NHS record unless the provider shares information with your GP
• the risk of encountering unregulated sellers if you do not check registration

What support looks like in practice

Medication is only one part of obesity treatment. All the licensed weight loss injections are intended to be used alongside a reduced-calorie diet and increased physical activity, and NICE expects NHS prescribing to be accompanied by this kind of support. How that support is delivered is one of the biggest practical differences between the two routes.

On the NHS

In a specialist (tier 3) weight management service, you might see a doctor, specialist nurse, dietitian, psychologist and sometimes a physiotherapist or exercise specialist. Appointments may be individual or in groups, face to face or remote. The service will look at your eating patterns, activity, sleep, mood and any medical conditions, and will plan treatment around them. For the primary care roll-out of Mounjaro, NHS England has required wraparound support for diet and physical activity, which local areas are delivering in different ways, including digital programmes.

People who do not qualify for medication may still be able to join lifestyle programmes. For example, the NHS Digital Weight Management Programme is available to some adults with obesity who also have diabetes, high blood pressure or both, through a GP or community pharmacy referral.

Privately

Private services vary much more. At a minimum, a regulated provider should:

• review your progress and side effects before each dose increase or repeat supply
• give clear advice on managing side effects and when to seek help
• provide a way to contact a clinician with concerns
• give advice on diet and activity alongside the medicine

Some providers go further, with dietitian consultations, health coaching, apps that track weight and protein intake, or structured programmes for maintaining weight after treatment. These services may be included in the price or charged separately. Ask what is included, and consider what you are likely to use. Our guides on protein on a GLP-1 and preserving muscle cover the kind of support that can help, whichever route you choose.

Why support matters

Clinical trials such as SURMOUNT-1 and STEP 1 provided lifestyle counselling to all participants, so the headline results reflect medication combined with support. Support also helps with the transition if treatment stops, because weight regain after stopping is common. See weight regain after stopping.

Regulation of private providers

Private weight loss services in the UK are regulated by several bodies:

• General Pharmaceutical Council (GPhC): regulates pharmacies and pharmacists in Great Britain. You can check a pharmacy on the GPhC register.
• Care Quality Commission (CQC): regulates online doctor and clinic services in England. Healthcare Inspectorate Wales, Healthcare Improvement Scotland and the RQIA in Northern Ireland do the same elsewhere.
• Professional regulators: the GMC (doctors), NMC (nurses) and GPhC (pharmacist prescribers) regulate the individual prescribers.
• MHRA: regulates medicines, including tackling fake and unlicensed products.
• ASA: enforces advertising rules, including the ban on promoting prescription-only medicines to the public.

The GPhC's 2025 guidance tightened expectations for online prescribing of weight loss medicines, including independent verification of key information and appropriate safeguards. See our guide to who regulates online weight loss services.

Moving between NHS and private care

From private to NHS

GPs are not usually obliged to take over prescribing started privately, and NHS prescribing of weight loss injections is restricted to people meeting NHS criteria. If you are being treated privately and think you may now qualify for NHS treatment, ask your GP for an assessment. Be aware that your BMI at the time of assessment may be lower because of the weight you have already lost; how this is handled can vary, so discuss it openly with your GP.

From NHS to private

If your NHS treatment ends, for example after the two-year limit for Wegovy under TA875, some people choose to continue privately. A private prescriber will carry out their own assessment and should consider your history, current dose and any break in treatment. See switching providers mid-treatment.

Keeping your GP informed

Whichever route you use, your GP should know you are taking a weight loss medicine. This matters for:

• prescribing other medicines safely, particularly diabetes medicines that can cause low blood sugar
• contraception, as tirzepatide may reduce the effectiveness of oral contraceptives
• planned surgery or procedures under anaesthesia
• monitoring conditions that may improve with weight loss, such as blood pressure

What the evidence says about results

The medicines themselves are the same whether prescribed on the NHS or privately. In the major trials:

• SURMOUNT-1: tirzepatide led to average weight loss of about 15% to 21% over 72 weeks, depending on dose.
• STEP 1: semaglutide 2.4mg led to average weight loss of about 15% over 68 weeks.

In these trials, the medicines were used alongside lifestyle support. Real-world results depend on how consistently treatment is taken, the dose reached, and the diet, activity and support around it. There is limited direct evidence comparing outcomes between NHS and private services, so claims that one route produces better results should be treated with caution.

Thinking about cost

On the NHS, your cost is limited to the standard prescription charge in England (unless you are exempt or use a prepayment certificate), and prescriptions are free in Scotland, Wales and Northern Ireland.

Privately, cost depends on:

• the medicine and dose (higher strengths are often priced higher)
• what the provider includes, such as consultations, needles and delivery
• how long you stay on treatment, which matters because weight is often regained after stopping (STEP 1 extension, SURMOUNT-4)

We do not quote prices. See how weight loss injection pricing works, the hidden costs of private treatment and our prices page. You can compare regulated private services on our providers page.

How to decide

These questions may help you think through the options with a professional:

1. Am I likely to meet NHS criteria now or in a future cohort? Ask your GP, and use our eligibility checker as a starting point (it is informational only).
2. How long is the local wait? For specialist services or primary care access.
3. What support do I need? If you would benefit from dietitian or psychological support, the NHS multidisciplinary model may be valuable; some private providers also offer this.
4. Can I sustain the cost? Think about months and years, not just the first month.
5. What matters most to me: speed, cost, support or choice?

It is also reasonable to do both: join an NHS waiting list or programme while discussing private options, as long as all prescribers know about any medicines you are taking.

When to speak to a professional

Start with your GP if you are considering weight loss treatment. They can check your BMI and health, discuss NHS options, refer you to local services and advise on whether private treatment might be suitable. Never take weight loss medicines from more than one source at the same time, and always tell your GP and any prescriber about all the medicines you use.

Seek urgent medical help (NHS 111, or 999 in an emergency) if you experience:

• severe, persistent abdominal pain, which may spread to your back, with or without vomiting (possible pancreatitis)
• pain in the upper right abdomen, fever, or yellowing of the skin or eyes (possible gallbladder problems)
• persistent vomiting or diarrhoea leading to signs of dehydration
• swelling of the face, lips or throat, or difficulty breathing
• symptoms of low blood sugar if you take diabetes medicines, such as shaking, sweating or confusion
• new or worsening low mood or thoughts of self-harm

Report suspected side effects to the MHRA through the Yellow Card scheme.